Former CEO and Co-Founder Charles Fisher will continue as Chief Scientist; Chief Commercial Officer Steve Herne will transition to CEO
After securing over $130M in funding and achieving multiple regulatory successes, Unlearn today announced changes to its executive leadership to support the commercial expansion of its innovative AI technologies. Effective immediately, CEO and Co‐Founder Charles Fisher will step into the role of Chief Scientist, where he will drive Unlearn’s product and technical innovation. Steve Herne, currently serving as the Chief Commercial Officer, will succeed Fisher as CEO.
"Since founding Unlearn in 2017, our primary focus has been advancing AI research and development to enable smaller, faster clinical trials. We did incredible work, creating the most innovative technologies in the entire clinical trial space. Now, we are entering the next phase—delivering AI products to solve key pain points across clinical development," said Charles Fisher, Ph.D. "Steve’s deep expertise in the pharmaceutical industry and ability to lead teams from research to product delivery make him the ideal person to guide Unlearn through this critical stage of growth."
Founded to advance AI to eliminate trial and error in medicine, Unlearn has grown over the last seven years into a leading AI company in clinical trials. Major global pharmaceutical companies have partnered with Unlearn, leveraging its digital twins of patients to accelerate their clinical research programs.
"Unlearn's dedication to modernizing outdated clinical research processes inspires me every day,” said Herne. “I’m honored to take on the role of CEO and build on the strong foundation Charles has established as he transitions into his new role. I look forward to working alongside Charles and the entire Unlearn team as we enter this exciting new phase of growth.”
For more information about Unlearn, visit: www.unlearn.ai
About Unlearn
Unlearn is a pioneering AI company with a product-driven focus, dedicated to transforming medicine by eliminating trial and error. The Unlearn Platform harnesses the power of digital twins—advanced computational models of patients—to empower pharmaceutical and biotech companies to overcome critical challenges in clinical development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240911790223/en/
Contacts
Alyssa Horowitz
unlearn@pancomm.com
